Exscientia plc (EXAI)
- Previous Close
4.94 - Open
4.99 - Bid 5.27 x 100
- Ask 5.33 x 100
- Day's Range
4.93 - 5.47 - 52 Week Range
3.86 - 9.12 - Volume
722,892 - Avg. Volume
617,249 - Market Cap (intraday)
669.788M - Beta (5Y Monthly) 0.82
- PE Ratio (TTM)
-- - EPS (TTM)
-1.33 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.33
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
www.exscientia.aiRecent News: EXAI
Performance Overview: EXAI
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EXAI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EXAI
Valuation Measures
Market Cap
624.29M
Enterprise Value
418.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
24.66
Price/Book (mrq)
2.04
Enterprise Value/Revenue
16.82
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.79%
Return on Equity (ttm)
-34.98%
Revenue (ttm)
20.08M
Net Income Avi to Common (ttm)
-145.96M
Diluted EPS (ttm)
-1.33
Balance Sheet and Cash Flow
Total Cash (mrq)
363.05M
Total Debt/Equity (mrq)
5.32%
Levered Free Cash Flow (ttm)
-116.44M